Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
Enrollment ongoing in Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease (with or without TED); Phase 2a topline results expected in the second half of 2027
Closed previously announced private financings totaling $200 million; expected to fund operations into 2028
Completed reverse merger with VYNE Therapeutics and commenced trading on Nasdaq under the ticker symbol “YARW”